Next 10 |
2024-05-09 22:40:25 ET Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Conference Call May 09, 2024, 17:00 ET Company Participants Vivian Wu - Associate Director, Investor Relations and Corporate Affairs Howard Robin - President, CEO & Director Jonathan Zal...
2024-05-09 16:22:16 ET More on Nektar Therapeutics Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript Nektar Therapeutics Q1 2024 Earnings Preview Seeking Alpha’s Qua...
Nektar Therapeutics Reports First Quarter 2024 Financial Results PR Newswire SAN FRANCISCO , May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024 . Cash and ...
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets PR Newswire SAN FRANCISCO , May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results fo...
2024-04-11 12:55:33 ET More on Mid-day movers & stocks. Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript Veru Inc. (VERU) Q1 2024 Earnings Call Transcript Veru gets Na...
2024-04-10 00:29:16 ET Summary Nektar Therapeutics' rezpegaldesleukin is now in two phase 2 studies, one in atopic dermatitis and one in alopecia areata. The phase 1b data in atopic dermatitis show promise, and a 400-patient phase 2 study in that indication will allow NKTR to exam...
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference PR Newswire SAN FRANCISCO ,...
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata PR Newswire SAN FRANCISCO , March 5, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biotechnology c...
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX PR Newswire SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
News, Short Squeeze, Breakout and More Instantly...
Nektar Therapeutics Reports First Quarter 2024 Financial Results PR Newswire SAN FRANCISCO , May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024 . Cash and ...
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets PR Newswire SAN FRANCISCO , May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results fo...
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference PR Newswire SAN FRANCISCO ,...